Literature DB >> 3986019

Lipoprotein distribution and composition in the human nephrotic syndrome.

E Muls, M Rosseneu, R Daneels, M Schurgers, J Boelaert.   

Abstract

Plasma lipoprotein profiles were quantitated in 9 patients with the nephrotic syndrome. Six subjects were studied both during an active proteinuric phase and during a remission phase without proteinuria. During the proteinuric phase, the plasma triglyceride, cholesterol and apo B levels were markedly increased, whereas the HDL cholesterol, apo A-I, and apo A-II concentrations were normal. Analysis of the distribution and composition of the lipoprotein subclasses, separated by isopycnic ultracentrifugation, showed typical patterns characterized by: (1) elevated apo B-rich VLDL and LDL fractions, (2) the presence of a denser LDL subfraction, floating at d 1.053 g/ml, which contained about 35% of LDL cholesterol and apo B and (3) a redistribution among HDL subclasses. The HDL2b (d 1.063-1.100 g/ml) fraction was markedly decreased, while the HDL2a + 3a (d 1.100-1.150 g/ml) and HDL3b + 3c (d 1.150-1.210 g/ml) subclasses were moderately elevated. The decreased cholesterol and apo A-I contents of HDL2b therefore counterbalanced their increase in HDL2a + 3a and HDL3b + 3c, resulting in normal plasma HDL cholesterol and apo A-I concentrations. When reinvestigated during a remission phase without proteinuria, the nephrotic patient's overall lipoprotein distribution and composition were similar to those in healthy controls. The combination of several factors such as the presence of elevated apo B-rich VLDL, IDL and LDL, together with decreased HDL2 cholesterol and HDL2 apo A-I suggests that nephrotic patients are at increased risk for atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3986019     DOI: 10.1016/0021-9150(85)90181-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

1.  Serum vitamin A, retinyl esters and vitamin E in nephrotic syndrome.

Authors:  M Mydlík; K Derzsiová; M Brátová; S Havris
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

Review 2.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

Review 3.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Authors:  Shipra Agrawal; Joshua J Zaritsky; Alessia Fornoni; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2017-11-27       Impact factor: 28.314

4.  Effect of methylprednisolone therapy on lipoprotein metabolism in human nephrotic syndrome.

Authors:  L Kuzemková; J Stríbrná; J Kovár; R Poledne; K Matousovic
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

5.  HDL and Kidney Diseases.

Authors:  Huanhuan Cao; Xia Meng
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 6.  [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].

Authors:  C J Olbricht
Journal:  Klin Wochenschr       Date:  1991-08-01

7.  Paraoxonase Activity and Lipid Profile in Paediatric Nephrotic Syndrome: A Cross-sectional Study.

Authors:  Vijayetha P Patil; Anuradha B Patil; Vidya S Patil; Deepti G Ingleshwar
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 8.  Lipid changes in the nephrotic syndrome: new insights into pathomechanisms and treatment.

Authors:  G D'Amico
Journal:  Klin Wochenschr       Date:  1991-09-03

Review 9.  HDL abnormalities in nephrotic syndrome and chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

10.  Lipoprotein profiles at different stages of the nephrotic syndrome.

Authors:  U Querfeld; A Gnasso; W Haberbosch; J Augustin; K Schärer
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.